Company Overview
Company Type: Public Company
Website: www.antibethera.com
Number of Employees: 11
Ticker: ATE (TSX)
Year Founded: 2009


Business Description
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The companyâ€™s pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
24.2
Total Enterprise Value
(10.1)
EBIT
(21.0)
Cash & ST Invst.
34.3
P/Diluted EPS Before Extra
NM
Net Income
(19.7)
Total Debt
0.0
Price/Tang BV
2.9x
Capital Expenditure
0.0
Total Assets
66.8




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.12)
(0.12)
(0.47)
(0.59)
(0.50)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
(5.80)
(5.80)
(21.23)
-
-

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
0.40x

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
1.69
Potential Upside
244.39%


Key Professionals
Name
Title
Legault, Daniel Marcel
President, CEO, Secretary & Director
Wilson, Alain 
Chief Financial Officer
Curtis, Scott 
Chief Operating Officer
Cameron, Christina 
Vice President of Investor Relations
Stern, Philip 
Vice President of Communications
Stauffer, Joseph 
Chief Medical Officer
Vaughan, David James
Chief Development Officer
Stegic, Ana 
Executive Director of Clinical Operations

Key Board Members
Name
Title
Hoffman, Robert E.
Independent Chair of the Board
Legault, Daniel Marcel
President, CEO, Secretary & Director
MacNee, Walter Minnes
Independent Vice Chair
Flower, Roderick John
Independent Director
Buret, Andre Gerald
Member of Scientific Advisory Board
Chan, Francis
Member of Clinical Advisory Board
Cirino, Giuseppe
Member of Scientific Advisory Board
de Nucci, Gilberto
Member of Scientific Advisory Board
Ernst, Peter B.
Member of Scientific Advisory Board
Gilroy, Derek 
Member of Scientific Advisory Board
Haut, Donald D.
Partnering Advisory Team
Hunt, Richard H.
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
15 Prince Arthur Avenue | Toronto, ON | M5R 1B2 | Canada
Phone: 416-922-3460   

Current and Pending Investors
AVAC Ltd., Bloom Burton Healthcare Lending Trust, MaRs Discovery District, Investment Arm

Prior Investors
AWM Investment Company Inc

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.49
Market Cap (mm)
25.8
Open
 0.46
Shares Out. (mm)
52.6
Previous Close
 0.49
Float %
94.0%
Change on Day
0.03
Shares Sold Short (mm)
-
Change % on Day
6.5%
Dividend Yield %
-
Day High/Low
 0.49/ 0.46
Diluted EPS Excl. Extra Items
(0.37)
52 wk High/Low
 0.69/ 0.41
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0062
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.17


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:ATE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-02-2022
Nov-01-2022
Merger/Acquisition
Seller
Citagenix Inc.
HANSAmed Limited
Antibe Therapeutics Inc. (TSX:ATE)
5.04
Feb-17-2021
Feb-24-2021
Public Offering
Target
Antibe Therapeutics Inc. (TSX:ATE)


27.96
Dec-4-2020
-
Shelf Registration
Target
Antibe Therapeutics Inc. (TSX:ATE)


50.00
Jun-9-2020
Jun-30-2020
Public Offering
Target
Antibe Therapeutics Inc. (TSX:ATE)


18.38
Jul-23-2019
Aug-13-2019
Public Offering
Target
Antibe Therapeutics Inc. (TSX:ATE)


6.08
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Product-Related Announcements
Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul
Sep-08-2023
Annual General Meeting
Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023
Jun-29-2023
Auditor Going Concern Doubts
Antibe Therapeutics Inc. Auditor Raises 'Going Concern' Doubt
May-02-2023
Company Conference Presentations
Antibe Therapeutics Inc. Presents at Precision in Clinical Trials Summit, May-02-2023 12:00 PM
Apr-26-2023
Company Conference Presentations
Antibe Therapeutics Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-26-2023 01:30 PM

Competitors
ACE Surgical Supply Co., Inc., AlloSource, Inc., Anika Therapeutics, Inc. (NasdaqGS:ANIK), Arthrex, Inc., Baxter International Inc. (NYSE:BAX), BioHorizons, Inc., Bioventus LLC, Dentsply IH AB, DePuy Synthes, Inc., Exactech, Inc., Geistlich Pharma AG, Genzyme Corporation Inc, Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Keystone Dental, Inc., LifeNet Health, Inc., Medtronic plc (NYSE:MDT), Medtronic, Inc., Musculoskeletal Transplant Foundation, Nobel Biocare Holding AG, NuVasive, Inc., Orthofix Medical Inc. (NasdaqGS:OFIX), Osteogenics Biomedical, Inc., Salvin Dental Specialties, Inc., Straumann Holding AG (SWX:STMN), Stryker Corporation (NYSE:SYK), Surgalign Holdings, Inc., Vericel Corporation (NasdaqGM:VCEL), Wright Medical Group N.V., Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

M&A Advisors
Norton Rose Fulbright Canada LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Norton Rose Fulbright Canada LLP
Private Placement Advisors
Bloom Burton & Co. Inc., D&D Securities Inc., Dundee Securities Ltd., Raymond James Ltd.
Public Offering Advisors
DeMarco Allan LLP, Ernst & Young LLP, Ernst & Young LLP (Canada), Fasken Martineau DuMoulin LLP, Norton Rose Fulbright Canada LLP, Troutman Pepper Hamilton Sanders LLP, WeirFoulds LLP, Zeifmans LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:54 AM
ATE
Antibe Therapeutics Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 05:58 AM
ATE
ValuEngine - Toronto Quantitative Stock Report for ATE
Reports
5
ValuEngine, Inc.

Oct 02, 2023 02:49 AM
ATE
ValuEngine Rating and Forecast Report for ATBPF
Reports
11
GlobalData

Sep 15, 2023 10:21 AM
ATE
Antibe Therapeutics Inc (ATBPF.OTC) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
92
GlobalData

Sep 15, 2023 05:34 AM
ATE
Antibe Therapeutics Inc (ATBPF.OTC) - Medical Devices Product Pipeline Summary
Reports
22
MarketLine

Sep 14, 2023 06:01 AM
ATE
Antibe Therapeutics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
102
GlobalData

Sep 13, 2023 02:01 AM
ATE
Antibe Therapeutics Inc (ATBPF.OTC) - Financial Analysis Review
Reports
222
S&P Global Compustat

Sep 07, 2023 03:48 AM
ATE
Antibe Therapeutics Inc 2023_09_07
Reports
15
GlobalData

Aug 29, 2023 01:48 AM
ATE
Antibe Therapeutics Inc (ATBPF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
62
GlobalData

Aug 29, 2023 01:45 AM
ATE
Antibe Therapeutics Inc (ATBPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
33


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Legault J.D., L.L.B., Daniel Marcel

1,109,396

2.11

0.5

Sep-12-2023


MacNee BA, MBA, Walter Minnes

502,360

0.95

0.2

Sep-12-2023


AltaPharm International Inc.

442,729

0.84

0.2

Jul-29-2022


Wu B.Sc., Yung C.

318,333

0.60

0.1

Sep-12-2023


NFQ Ventures

240,000

0.46

0.1

Jul-28-2023


Stauffer D.O., M.B.A., Joseph 

186,153

0.35

0.1

Sep-12-2023


Flower B.Sc., BSc, FRS DSc, Ph.D., Roderick John

170,135

0.32

0.1

Sep-12-2023


Curtis C.F.A., M.Eng, Scott 

100,000

0.19

0.0

Sep-12-2023


The Elegen Group Inc

99,092

0.19

0.0

Sep-12-2023


Wilson M.B.A., MBA, Alain 

68,918

0.13

0.0

Nov-28-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Stauffer D.O., M.B.A., Joseph 
186,153
16,666
Stegic, Ana 
40,033
3,333

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ATB-340 (Future), ATB-352 (Future), ATB-429 (Future), CGX-227 (Future), CGX-443 (Future), Licensing of ATB-340, Licensing of ATB-352, Licensing of Otenaproxesul, Otenaproxesul (Future), URIST (Future)


Upcoming Events
Date/Time
Type
Nov-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-28-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
News Releases
201 KB
Sep-08-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
News Releases
73 KB
Sep-08-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Management Proxy Materials
100 KB
Aug-14-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
News Releases
89 KB
Aug-14-2023
Jun-30-2023
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Interim Financial Statements
381 KB
Aug-02-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Management Proxy Materials
71 KB
Aug-02-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Management Proxy Materials
132 KB
Aug-02-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Management Proxy Materials
115 KB
Aug-02-2023
-
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Management Proxy Materials
1006 KB
Jun-30-2023
Mar-31-2023
Antibe Therapeutics Inc. (TSX:ATE)
SEDAR
Annual Financial Statements
155 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Stauffer D.O., M.B.A., Joseph  (Chief Medical Officer)
May-01-2023
Common Shares
16,666
9,083
Derivative Exercise and Retained Stock
9.83
Multiple
Stegic, Ana  (Executive Director of Clinical Operations)
May-01-2023
Common Shares
3,333
1,816
Derivative Exercise and Retained Stock
9.08
Multiple
Stauffer D.O., M.B.A., Joseph  (Chief Medical Officer)
Mar-03-2023
Common Shares
16,667
8,536
Derivative Exercise and Retained Stock
10.91
Multiple
Hoffman B.B.A., CPA, CPA, Robert E. (Independent Chair of the Board)
Jan-11-2023
Common Shares
11,667
7,009
Derivative Exercise and Retained Stock
87.50
Multiple
Flower B.Sc., BSc, FRS DSc, Ph.D., Roderick John (Independent Director)
Jan-11-2023
Common Shares
13,333
8,010
Derivative Exercise and Retained Stock
8.50
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Hoffman, Robert E.
Independent Chair of the Board
416-922-3460
-
rhoffman@kintara.com
Legault, Daniel Marcel
President, CEO, Secretary & Director
416-922-3460
-
dan.legault@antibethera.com
MacNee, Walter Minnes
Independent Vice Chair
416-922-3460
-

Flower, Roderick John
Independent Director
416-922-3460
-

Buret, Andre Gerald
Member of Scientific Advisory Board
416-922-3460
-
a.buret@antibe-therapeutics.com
Chan, Francis
Member of Clinical Advisory Board
416-922-3460
-
-
Cirino, Giuseppe
Member of Scientific Advisory Board
416-922-3460
-
-
de Nucci, Gilberto
Member of Scientific Advisory Board
416-922-3460
-
-
Ernst, Peter B.
Member of Scientific Advisory Board
416-922-3460
-
-
Gilroy, Derek 
Member of Scientific Advisory Board
416-922-3460
-

Haut, Donald D.
Partnering Advisory Team
416-922-3460
-

Hunt, Richard H.
Member of Scientific Advisory Board
416-922-3460
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Legault, Daniel Marcel
President, CEO, Secretary & Director
416-922-3460
-
dan.legault@antibethera.com
Wilson, Alain 
Chief Financial Officer
+ 416 456 6770
-
a.wilson@antibe-therapeutics.com
Curtis, Scott 
Chief Operating Officer
416-922-3460
-

Cameron, Christina 
Vice President of Investor Relations
(141) 657-7144x3
-
christina@antibethera.com
Stern, Philip 
Vice President of Communications
(416) 588-0000
-
-
Stauffer, Joseph 
Chief Medical Officer
416-922-3460
-

Vaughan, David James
Chief Development Officer
416-922-3460
-

Stegic, Ana 
Executive Director of Clinical Operations
416-922-3460
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
